FDA’s Digital Liver Break: How AI Toxicology Could Change Drug Development Before Phase I | Witfire Elite View Witfire Elite FDA & Regulatory Case Studies Strategy Long Read FDA & Regulatory Intelligence Witfire Elite View FDA’s Digital Liver Break How AI Toxicology Could Change Drug Development Before Phase I FDA accepted the first in silico […]
The China Biotech Pipeline Grab: How Big Pharma Started Buying Innovation From China | Witfire Elite View Witfire Elite Pharma Markets Case Studies Strategy Long Read Pharma Market Case Study Witfire Elite View The China Biotech Pipeline Grab How Big Pharma Started Buying Innovation From China A data-heavy pharma case study on how Pfizer, BMS,
The China Biotech Pipeline Grab: How Big Pharma Started Buying Innovation From China Read More »
The Pharma Tariff War: How US Drug Pricing Pressure Is Forcing Big Pharma to Rewrite Global Strategy | Witfire Elite View Witfire Elite Pharma Markets Case Studies Strategy Long Read Pharma Market Case Study Witfire Elite View The Pharma Tariff War How US Drug Pricing Pressure Is Forcing Big Pharma to Rewrite Global Strategy A
How GLP-1 Became Pharma’s Most Powerful Growth Story
How GLP-1 Became Pharma’s Most Powerful Growth Story Read More »
GLP-1 Market: The obesity and diabetes drug race is becoming one of the biggest business stories in global pharma. Reuters reported that analysts now estimate global obesity drug sales around USD 105 billion by 2030, lower than earlier USD 130 billion forecasts because of expected price pressure and changing usage patterns. IQVIA’s obesity outlook is
GLP-1 Market Becomes Pharma’s Biggest Business Battle Read More »
